This month's edition of the HDYO Research Series focuses on the HD Buzz article exploring Casgevy, the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and it’s paving the way for similar drugs targeting other diseases. Is Huntington’s disease next?
To read this complete article, visit: https://en.hdbuzz.net/356
Research Video Series sponsors: Roche, Sage Therapeutics, Teva Pharmaceuticals, uniQure, Wave Life Sciences, Griffin Foundation and Neurocrine Biosciences.